Use of the newer antiarrhythmic drugs in patients with supraventricular tachyarrhythmias: Let's not throw out the baby with the bath water

Canadian Journal of Cardiology

Volumn 12, Issue 10, 1996, Pages 972-982

  Mitchell, L Brent ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Amiodarone; Atrial fibrillation; Flecainide; Propafenone; Sotalol; Supraventricular tachyarrhythmias; Supraventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BEPRIDIL; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; LIDOCAINE; METOPROLOL; MEXILETINE; PHENYTOIN; PINDOLOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; VERAPAMIL;

ARRHYTHMOGENESIS; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY ATHEROSCLEROSIS; DRUG USE; ELECTROPHYSIOLOGY; FATIGUE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; NAUSEA; NEUROPATHY; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY DISORDER; PNEUMONIA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TASTE DISORDER; VERTIGO; VISUAL DISORDER;

ANTI-ARRHYTHMIA AGENTS; HUMANS; RECURRENCE; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 0029797996     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Ostrander L, Brandt RL, Kjelsberg MD, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumsch, Michigan. Circulation 1965;31:888-98.
2. Kulbertus HE, Laval-Rutten FD, Bartsch P, Petit J. Atrial fibrillation in elderly, ambulatory patients. In: Kulbertus H, Olsson S, Schlepper M, eds. Atrial Fibrillation. Molndal: AB Hassle, 1982:148-57.
3. Wang Z, Page P, Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992;71:271-87.
4. Klein GJ, Guiraudon GM, Sharma AD, Milstein S. Demonstration of macroreentry and feasibility of operative therapy in the common type of atrial flutter. Am J Cardiol 1986;57:587-91.
5. Rosen MR. Mechanisms for arrhythmias. Am J Cardiol 1988;61:2A-8A
6. Akhtar M, Jazayeri MR, Sra J, Blanck Z, Deshpande S, Dhala A. Atrioventricular nodal reentry: Clinical, electrophysiological, and therapeutic considerations. Circulation 1993;88:282-95.
7. Gallagher JJ, Pritchett ELC, Sealy WC, Kasell J, Wallace AC. The preexcitation syndromes. Prog Cardiovasc Dis 1978;20:285-326.
8. Kalbfleisch SJ, el-Atassi R, Calkins H, Langberg JJ, Morady F. Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram. J Am Coll Cardiol 1993,21:85-9.
9. Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301:1080-5.
10. Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome: Analysis during atrial fibrillation. Circulation 1977;56:260-7.
11. Gulamhusem S, Ko P, Carruthers G, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982;65:348-54.
12. Morady F, DiCarlo LA Jr, Baerman JM, De Buitleir M. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. PACE 1987;10:492-6.
13. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
14. Task Force of the Working Group an Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.
15. Zipes DP. Proarrhythmic events. Am J Cardiol 1988;61:70A-6A.
16. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: Mechanisms and management. Drugs 1994;47:51-65.
17. Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986;8:73A-8A.
18. Hohnloser SH, Arendts W, Quart B. Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF. PACE 1992,15:551. (Abst)
19. Hu JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes: Disparate effects of Class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-82.
20. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992,117:141-50
21. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encamide, flecainide, or placebo. N Engl J Med 1991;324:781-8.
22. The Cardiac Arrhythmia Suppression Trial Investigators. Failure of treatment with moricizine to improve survival in a randomized trial of arrhythmia suppression after myocardial infarction: the Cardiac Arrhythmia Suppression Trial II. N Engl J Med 1992;327:227-33.
23. Hallstrom AP, Anderson JL, Carlson M, et al. Time to arrhythmic, ischemic, and heart failure events: Exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. Am Heart J 1995;130:71-9.
24. Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991;67:976-80.
25. Pritchett ELC, Wilkinson WE, Clair WK, McCarthy EA. Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. Am J Cardiol 1993;72:108-10.
26. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-16
27. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32.
28. Smith TW. Digitalis: Mechanisms of action and clinical use. N Engl J Med 1988;318:358-65.
29. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter. J Am Coll Cardiol 1991;18:891-7.
30. Roden DM, Woosley RL. Flecainide. N Engl J Med 1986;315:36-41.
31. Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3A-10A.
32. Madrid AH, Moro C, Marin-Huerta E, Mestre L, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-31.
33. Capucct A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
34. Anderson JL, Gilbert EM, Alpert BL, et al. Flecainide Supraventricular Tachycardia Study Group. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-70.
35. Henthom RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation 1991;83.119-25
36. Steinbeck G, Doliwa R, Bach P. Therapie des paroxysmalen vorhofflimmerns. Herzglykoside allein oder in kombination mit antiarrhythmika? Dstch Med Wochenscher 1988;133:1867-71.
37. Lau C-P, Leung W-H, Wong C-K. A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992;124:645-50.
38. Naccarelli GV, Dorian P, Hohnloser SH, et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxvsmal atrial fibrillation/flutter. Am J Cardiol 1996;17:53A-9A.
39. Bryson HM, Palmer KJ, Langtry HD, Fitton A. Propafenone: A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993;45:85-130.
40. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990;16.1408-14.
41. Bertini G, Conti A, Fradella G, et al. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med 1990;8:15-20.
42. Negrini M, Gibelli G, de Ponti C. A comparison of propafenone and amiodarone in reversion of recent-onset atrial fibrillation to sinus rhythm. Curr Ther Res 1994;55:1345-54.
43. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnant B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994;43:305-13.
44. Capucci A, Boriani G, Botto GL, et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 1994;74:503-5.
45. Richiardi E, Gaita F, Greco C, et al. Propafenone versus quinidine in long-term prophylaxis of atrial fibrillation. Cardiologia 1992;37:123-7.
46. Chimienti M, Cullen MT Jr, Casadei G, Flecainide and Propafenone Italian Study Group. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 1996,77:60A-5A.
47. Aliot E, Denjoy I, Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal. Am J Cardiol 1996;77:66A-71A.
48. Reimhold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-63.
49. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994;331:31-8.
50. MacNeil, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A-50A.
51. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-9.
52. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66.
53. Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-9.
54. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;72:75F-81F
55. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy for refractory symptomatic atrial fibrillation and atrial flutter a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
56. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335-41.
57. Sung RJ, Elser B, McAllister RJ Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias. Ann Intern Med 1980;93;682-9.
58. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine: Basic and clinical concepts. Circulation 1991;83:1499-509.
59. Grosselink ATM, Crijns HJGM, Van Den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1194;72:161-6.
60. Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1290-5.